+

WO1998008524A1 - Produits multimineraux utiles pour atteindre un equilibre nerveux - Google Patents

Produits multimineraux utiles pour atteindre un equilibre nerveux Download PDF

Info

Publication number
WO1998008524A1
WO1998008524A1 PCT/US1997/014967 US9714967W WO9808524A1 WO 1998008524 A1 WO1998008524 A1 WO 1998008524A1 US 9714967 W US9714967 W US 9714967W WO 9808524 A1 WO9808524 A1 WO 9808524A1
Authority
WO
WIPO (PCT)
Prior art keywords
meg
composition according
minerals
vary
levels
Prior art date
Application number
PCT/US1997/014967
Other languages
English (en)
Inventor
Nicholas James Gonzalez
Linda Lee Isaacs
Original Assignee
Nicholas James Gonzalez
Linda Lee Isaacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas James Gonzalez, Linda Lee Isaacs filed Critical Nicholas James Gonzalez
Priority to AU41621/97A priority Critical patent/AU4162197A/en
Publication of WO1998008524A1 publication Critical patent/WO1998008524A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Definitions

  • the present invention relates generally to multimineral products.
  • the present inventors have found that by using certain minerals at certain levels in a unit dose provides for enhanced performance. This is different from the prior art since balancing the autonomic nervous system is targeted for the first time. That a purpose of the present invention is to provide unit doses of minerals.
  • That a further purpose is to provide unit doses of minerals containing levels of minerals which vary depending on the individual characteristics as discussed above.
  • That a further objective of the present invention is to provide methods of combating diseases by using such unit doses.
  • the present invention relates to multimineral compositions in unit dose form. Detailed Description Of The Invention
  • the unit dose compositions comprise a multiple of minerals.
  • the history of minerals and their properties are given in greater detail below:
  • the minerals used in the present compositions include the following: Boron Between 1939 and 1947, several attempts to induce a boron deficiency in rats were unsuccessful. As a result, boron was generally accepted as essential for plants (suggested in 1910, confirmed in 1923), but not for animals. Since 1982, however, evidence has accumulated that indicates boron is an essential nutrient for animals and humans.
  • the target level of Boron used in the compositions of the present invention is about 150 meg in the products for balanced vegetarian and about 160 meg in the products for balanced carnivore.
  • Calcium The role of calcium as a structural material in bones and teeth has been known for centuries. Prehistoric man suffered from osteoporosis, and although great progress has been made in the last few decades toward quantifying and understanding this disease, much remains to be understood about the importance of dietary calcium intake as a causative, preventative, or therapeutic factor. In addition to calcium's structural role in bone and teeth, it is now recognized that all living cells require calcium to conduct their specialized functions. Intracellular calcium acts as a second messenger and enables cells to respond to stimuli such as hormones or neurotransmitters. Movement of calcium from intracellular compartments to the cytosol initiates events such as cell division, secretion, a . nd movement.
  • the target level of Calcium used in the compositions of the present invention is about 90 mg in the products for balanced vegetarian and about 275 mg in the products for balanced carnivore.
  • Chromium By 1948, chromium was recognized as a consistent component of plant and animal tissue. The first suggestion that chromium might have biologic activity appeared in 1954, when it was found that chromium enhanced the synthesis of cholesterol and fatty acids from acetate by rat liver. In 1959, trivalent chromium was identified as the active component of the "glucose tolerance factor," which alleviated the impaired glucose tolerance in rats fed certain diets apparently inadequate in chromium. Between 1964 and 1968, the first reports appeared that indicated chromium could affect glucose tolerance in humans.
  • Copper Copper hias been used therapeutically smce at least 400 B.C., when Hippocrates prescribed copper compounds for pulmonary and other diseases.
  • the use of copper compounds in the treatment of diseases reached its peak in the nineteenth century and subsequently declined when the treatments were not successful.
  • an anemia that could not be prevented by iron supplements has been observed in animals kept on a whole-milk diet.
  • Hart reported that this anemia in rats was responsive to iron only when copper supplements were also given.
  • Experiments in several animals species produced similar results and suggested that copper deficiency anemia occurs in all species. Detailed reviews of the early history of copper have been published.
  • the target level of Copper used in the compositions of the present invention is about 0.50 mg in the products for balanced vegetarian and about 0.30 mg in the products for balanced carnivore.
  • Germanium Grayish-white solid, a p-type semiconductor, conductivity depends largely on added impurities, d 5.323, p 937.4C, bp 2830C, oxidizes readily at 600-700C, does not volatilize approximately 1350C, hardness 6 on Mohs scale. Attached by nitric acid and aqua regia, stable to water, acids and alkalies in absence of dissolved oxygen.
  • the target level of Germanium used in the compositions of the present invention is about 9.0 mg in the products for balanced vegetarian and about 8.0 mg in the products for balanced carnivore.
  • Magnesium Magnesium plays an essential role in a wide range of fundamental cellular reactions. Hence, it is not surprising that deficiency in the organism may lead to serious biochemical and symptomatic changes. McCollum and associates made the first systematic observations of magnesium deficiency in rats and dogs in the early 1930s. The first description of clinical depletion in man was published in 1934 in a small number of patients with various underlying diseases. Flink and associates in the early 1950s initiated their long-term studies documenting depletion of this ion in alcoholics and in patients on magnesium-free intravenous solutions.
  • the target level of Magnesium used in the compositions of the present invention is about 90 mg in the products for balanced vegetarian and about 30 mg in the products for balanced carnivore.
  • the target level of Manganese used in the compositions of the present invention is about 9.0 mg in the products for balanced vegetarian and about 10 mg in the products for balanced carnivore.
  • the target level of Molybdenum used in the compositions of the present invention is about 34 meg in the products for balanced vegetarian and about 34 meg in the products for balanced carnivore.
  • Potassium Potassium is the most abundant intracellular cation, with an average concentration of about 150 mEq L; the extracellular concentration ranges from 3.5 to 5 mEq/L.
  • the average total exchangeable potassium for hospitalized adult males is 42.7 mEq kg body weight, whereas the future for women is about 10% less.
  • the normal value of total exchangeable potassium is 8 to 15% less than that of total body potassium.
  • the transmembrane electrical potential of most cells is determined by the ratio of intracellular to extracellular potassium concentration; in muscle the transmembrane electrical potential is about 90mv with the inside of the cell negative to the outside
  • the membrane potential (E m ) is calculated from the Nernst equation
  • Potassium being the major intracellular ion, is the mam determinant of intracellular ionic strength Cellular ionic strength greatly influences cellular metabolism as evidenced by the marked clinical abnormalities attributable to cell overhydration or dehydration In addition, potassium has specific roles in various enzymatic reactions of the cell, such as in protein and glycogen synthesis.
  • the target level of Potassium used in the compositions of the present invention is about 35 mg in the products for balanced vegetarian and about 15 mg in the products for balanced carnivore
  • the target level of Selenium used in the compositions of the present invention is about 35 meg in the products for balanced vegetarian and about 40 meg in the products for balanced carnivore.
  • Silica Colorless crystals or white powder, odorless and tasteless, d 2 2-2 6, insoluble in water and acids except hydrogen fluoride, soluble in molten aikai when finely divided and .amorphous Combines chemically with most metallic oxides; melts to a glass with lowest known coefficient of expansion (fused silica); thermal conductivity about half that of glass, mp 171 OC, bp 2230C, high dielectric constant, high heat and shock resistance
  • the target level of Silica used in the compositions of the present invention is about 5 0 mg in the products for balanced vegetarian and about 2 0 mg in the products for balanced carnivore Vanadium In 1876, Priestly reported on the toxicity of sodium vanadate.
  • vanadium is an essential nutrient. Many of these findings, however, may have been the consequence of high vanadium supplements (10 to 100 times the amount normally found in the diet) that induced pharmacologic changes in suboptimaily performing animals fed unbalanced diets. The most substantive evidence for vanadium essentiality has appeared only since 1987.
  • the target level of Vanadium used in the compositions of the present invention is about 18 meg in the products for balanced vegetarian and about 22 meg in the products for balanced carnivore.
  • Zinc Zinc (Zn) was recognized as a distinct element in 1509. Evidence of its essentiality was demonstrated in plants in 1869 and in animals in 1934. Because of its wide prevalence in foodstuffs, naturally occurring Zn deficiency was considered unlikely until 1955, when swine parakeratosis was shown to be a Zn-deficiency disease. That humans could suffer from Zn deficiency was suggested by observations that malnourished Chinese patients during World War II had low concentrations of plasma Zn. In 1956, a conditioned Zn-deficiency syndrome in humans was demonstrated.
  • the target level of Zinc used in the compositions of the present invention is about 12.0 mg in the products for balanced vegetarian and about 12.0 mg in the products for balanced carnivore.
  • Suitable additional components include such materials as carboxymethyl cellulose.
  • the minerals can simply be mixed together in a dry state and put into a suitable unit dose delivery device such as a capsule, sachet or other unit dose which does not involve significant compression.
  • a suitable unit dose delivery device such as a capsule, sachet or other unit dose which does not involve significant compression.
  • the unit doses can also be mixed with an appropriate solvent such as water to form a solution or suspension before use and can be used by patients who prefer liquids or are unable to take materials by mouth through use of intravenous or peroneal infusion.
  • compositions of the present invention are ingested in the same manner as other unit doses are. Oftentimes, the unit dose is ingested with the aid of water or other liquid.
  • composition described in the Examples can be dosed in one single dose or in multiple doses, such as two or three or more, so long as the total dosage amount is met.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

L'invention concerne des produits multiminéraux destinés à des groupes spécifiques ciblés.
PCT/US1997/014967 1996-08-26 1997-08-26 Produits multimineraux utiles pour atteindre un equilibre nerveux WO1998008524A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41621/97A AU4162197A (en) 1996-08-26 1997-08-26 Multimineral products useful in achieving autonomic balance

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70330896A 1996-08-26 1996-08-26
US08/703,308 1996-08-26
US74454996A 1996-11-06 1996-11-06
US08/744,549 1996-11-06
US83310997A 1997-04-04 1997-04-04
US08/833,109 1997-04-04

Publications (1)

Publication Number Publication Date
WO1998008524A1 true WO1998008524A1 (fr) 1998-03-05

Family

ID=27418757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014967 WO1998008524A1 (fr) 1996-08-26 1997-08-26 Produits multimineraux utiles pour atteindre un equilibre nerveux

Country Status (6)

Country Link
AU (1) AU4162197A (fr)
CO (1) CO4900076A1 (fr)
ID (1) ID19681A (fr)
MA (1) MA24992A1 (fr)
PE (1) PE24899A1 (fr)
WO (1) WO1998008524A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916270A2 (fr) * 1997-11-18 1999-05-19 EnergyBalance AG Mélange de minéraux dont le goût est amélioré
EP1124438A1 (fr) * 1998-11-06 2001-08-22 Nucycle Therapy Inc. Supplements nutritionnels

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002867A1 (fr) * 1985-11-14 1987-05-21 Vita Tech International, Inc. Produits chelates a base de proteines hydrolisees
WO1993002682A1 (fr) * 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Procede et compositions reduisant le besoin d'alcool et de stimulants
US5597550A (en) * 1994-12-09 1997-01-28 Buxing Mo Apparatus and method for administering minerals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002867A1 (fr) * 1985-11-14 1987-05-21 Vita Tech International, Inc. Produits chelates a base de proteines hydrolisees
WO1993002682A1 (fr) * 1991-08-06 1993-02-18 Labco Pharmaceuticals, Inc. Procede et compositions reduisant le besoin d'alcool et de stimulants
US5597550A (en) * 1994-12-09 1997-01-28 Buxing Mo Apparatus and method for administering minerals

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916270A2 (fr) * 1997-11-18 1999-05-19 EnergyBalance AG Mélange de minéraux dont le goût est amélioré
EP0916270A3 (fr) * 1997-11-18 1999-12-08 EnergyBalance AG Mélange de minéraux dont le goût est amélioré
EP1124438A1 (fr) * 1998-11-06 2001-08-22 Nucycle Therapy Inc. Supplements nutritionnels
EP1124438A4 (fr) * 1998-11-06 2005-02-02 Nucycle Therapy Inc Supplements nutritionnels

Also Published As

Publication number Publication date
ID19681A (id) 1998-07-30
CO4900076A1 (es) 2000-03-27
PE24899A1 (es) 1999-03-17
MA24992A1 (fr) 2000-07-01
AU4162197A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
AU2010212456B2 (en) Formulas comprising calcium, magnesium, zinc, and vitamin D3, for the prevention and amelioration of osteoporosis
RU2309751C1 (ru) Способ лечения нарушений минерального обмена при артрите, или остеохондрозе, или рахите, или артрозе, или остеопорозе
Nordstrom Trace mineral nutrition in the elderly
EP1003370B1 (fr) Procede permettant d'ameliorer l'absorption du magnesium et de prevenir l'atherosclerose
CN101642468A (zh) 用于降低血糖和血脂的药物组合物
KR20100103520A (ko) 고령자의 영양 상태 개선, 발열 횟수의 저하 및/또는 면역능 향상을 위한 조성물
WO1998008524A1 (fr) Produits multimineraux utiles pour atteindre un equilibre nerveux
US20070042020A1 (en) Composition for the treatment of dysfunctional energy metabolism syndrome
CN112544847A (zh) 一种增强耐力的运动固体饮料及其制备方法
Linder Other trace elements and the liver
US4591506A (en) Oral ingestion of indium
EP2606900A1 (fr) Augmentation de la prise de magnesium chez des mammiferes
EP1675598B1 (fr) Composition d'oligo-elements destines a l'alimentation
CN101601681A (zh) 用于降低血糖和血脂的药物组合物
JPS62171654A (ja) 細胞代謝を向上させる組成物
Solomons Trace elements in nutrition of the elderly: 1. Established RDAs for iron, zinc, and iodine
Anderson et al. EDTA chelation therapy does not selectively increase chromium losses
Belavady Amino acid imbalance and pellagra
CN101584736A (zh) 用于降低血糖与血脂和治疗糖尿病的药物组合物
Ling News Details
CN108514122A (zh) 矿物质补充制剂的制备方法
Watson Trace Element Requirements of the Elderly
Kassam et al. A new form of speudohypoparathyroidism type II with abnormal response to TRH: 37
CN101632716A (zh) 用于降低血糖的药物组合物
CN101579442A (zh) 用于降低血糖和血脂的药物组合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511814

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载